엘앤씨바이오
290650KOSDAQ의약품 제조업50.3 / 100
Reference Date: 2026-07-24
Company InformationBased on 2025 Annual Report
Business Overview
L&N Bio is a specialist in regenerative medicine, developing and selling human tissue implants and medical devices, along with cosmetic and pharmaceutical businesses. Its flagship product, Acellular Dermal Matrix (MegaDerm), is used for breast reconstruction after cancer treatment, and the company expands its global market by exporting tissue-based medical devices. It aims to grow into a comprehensive healthcare platform through R&D in regenerative medicine.
Number of Employees
155people
Average Salary
49.8M KRW
Score Calculation Basis
Detailed Financial Score
10.1x industry avg (risky)
Well below industry avg
Half of industry avg (excellent)
Avg ▲11.6% (2-year basis)
Avg ▲3.3% (2-year basis)
Avg ROE 14.6% (declining, 3yr)
Detailed News Sentiment
- Positive엘앤씨바이오 메가너브, 대학병원 40여 곳 도입…동종신경이식재 시장.....
엘앤씨바이오의 메가너브가 주요 대학병원 40여 곳에 도입되어 신경재건 분야에서의 시장 확대와 기술력 인정을 받았다.
- Positive코스피, 5% 급등 후 횡보…코스닥은 하락 후 상승
엘앤씨바이오를 포함한 코스피 지수가 외국인 매수세로 인해 급등했으나, 엘앤씨바이오에 대한 직접적인 영향은 명시되지 않았다.
- Positive코스피, 5% 넘게 급등…올해 20번째 매수사이드카
엘앤씨바이오를 포함한 코스피 지수가 외국인 매수세로 인해 급등했다.
Detailed Momentum
52w lower range (37%)
1m -33.01% (strong drop)
Volume decreasing